rabbit polyclonal anti-u2af2 a303-665a Search Results


rabbit polyclonal anti-u2af2 a303-665a  (Bethyl)
90
Bethyl rabbit polyclonal anti-u2af2 a303-665a
KEY RESOURCES TABLE
Rabbit Polyclonal Anti U2af2 A303 665a, supplied by Bethyl, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit polyclonal anti-u2af2 a303-665a/product/Bethyl
Average 90 stars, based on 1 article reviews
rabbit polyclonal anti-u2af2 a303-665a - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
brd9  (Bethyl)
94
Bethyl brd9
( a ) Unsupervised clustering of patient samples based on events differentially spliced in UVM (MEL270) and myeloid leukemia (K562) cells expressing SF3B1 K700E versus WT. PSI, percent spliced in (fraction of mRNA corresponding to mutant SF3B1-promoted isoform), with per-event, per-cohort range normalization. TCGA, The Cancer Genome Atlas. ( b ) Genes for which mutant SF3B1 promotes an NMD isoform (a3ss and se events only) in one or more cohorts. ( c ) CRISPR/Cas9-based positive selection screen targeting genes for which mutant SF3B1 promotes an NMD isoform. ( d ) Per-gene scatter plot comparing CRISPR screen enrichment (y axis) to differential splicing in TCGA UVM cohort (x axis). Pten , positive control. n=6 biologically independent experiments. Per-gene significance computed with two-sided CAMERA test. FDR computed with Benjamini-Hochberg method. ( e ) <t>BRD9</t> RNA-seq read coverage in patient samples. N, number of patients. PE, BRD9 poison exon; 14 and 15, flanking constitutive exons. Repetitive elements from RepeatMasker . ( f ) Western blot for N-terminal HA-tagged endogenous BRD9 in MEL270 cells transduced with empty vector (EV) or doxycycline-inducible FLAG-SF3B1-WT/K700E. Representative images from n=3 biologically independent experiments.
Brd9, supplied by Bethyl, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/brd9/product/Bethyl
Average 94 stars, based on 1 article reviews
brd9 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
brm  (Bethyl)
93
Bethyl brm
( a ) Unsupervised clustering of patient samples based on events differentially spliced in UVM (MEL270) and myeloid leukemia (K562) cells expressing SF3B1 K700E versus WT. PSI, percent spliced in (fraction of mRNA corresponding to mutant SF3B1-promoted isoform), with per-event, per-cohort range normalization. TCGA, The Cancer Genome Atlas. ( b ) Genes for which mutant SF3B1 promotes an NMD isoform (a3ss and se events only) in one or more cohorts. ( c ) CRISPR/Cas9-based positive selection screen targeting genes for which mutant SF3B1 promotes an NMD isoform. ( d ) Per-gene scatter plot comparing CRISPR screen enrichment (y axis) to differential splicing in TCGA UVM cohort (x axis). Pten , positive control. n=6 biologically independent experiments. Per-gene significance computed with two-sided CAMERA test. FDR computed with Benjamini-Hochberg method. ( e ) <t>BRD9</t> RNA-seq read coverage in patient samples. N, number of patients. PE, BRD9 poison exon; 14 and 15, flanking constitutive exons. Repetitive elements from RepeatMasker . ( f ) Western blot for N-terminal HA-tagged endogenous BRD9 in MEL270 cells transduced with empty vector (EV) or doxycycline-inducible FLAG-SF3B1-WT/K700E. Representative images from n=3 biologically independent experiments.
Brm, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/brm/product/Bethyl
Average 93 stars, based on 1 article reviews
brm - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


KEY RESOURCES TABLE

Journal: Cell

Article Title: Pervasive Chromatin-RNA Binding Protein Interactions Enable RNA-Based Regulation of Transcription

doi: 10.1016/j.cell.2019.06.001

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Rabbit polyclonal anti-U2AF2 , Bethyl , A303-665A; RRID: AB_11204941.

Techniques: Recombinant, Protease Inhibitor, Magnetic Beads, Staining, Blocking Assay, Ligation, Purification, Gel Extraction, Imaging, Sequencing, Software

( a ) Unsupervised clustering of patient samples based on events differentially spliced in UVM (MEL270) and myeloid leukemia (K562) cells expressing SF3B1 K700E versus WT. PSI, percent spliced in (fraction of mRNA corresponding to mutant SF3B1-promoted isoform), with per-event, per-cohort range normalization. TCGA, The Cancer Genome Atlas. ( b ) Genes for which mutant SF3B1 promotes an NMD isoform (a3ss and se events only) in one or more cohorts. ( c ) CRISPR/Cas9-based positive selection screen targeting genes for which mutant SF3B1 promotes an NMD isoform. ( d ) Per-gene scatter plot comparing CRISPR screen enrichment (y axis) to differential splicing in TCGA UVM cohort (x axis). Pten , positive control. n=6 biologically independent experiments. Per-gene significance computed with two-sided CAMERA test. FDR computed with Benjamini-Hochberg method. ( e ) BRD9 RNA-seq read coverage in patient samples. N, number of patients. PE, BRD9 poison exon; 14 and 15, flanking constitutive exons. Repetitive elements from RepeatMasker . ( f ) Western blot for N-terminal HA-tagged endogenous BRD9 in MEL270 cells transduced with empty vector (EV) or doxycycline-inducible FLAG-SF3B1-WT/K700E. Representative images from n=3 biologically independent experiments.

Journal: Nature

Article Title: Spliceosomal disruption of the non-canonical BAF complex in cancer

doi: 10.1038/s41586-019-1646-9

Figure Lengend Snippet: ( a ) Unsupervised clustering of patient samples based on events differentially spliced in UVM (MEL270) and myeloid leukemia (K562) cells expressing SF3B1 K700E versus WT. PSI, percent spliced in (fraction of mRNA corresponding to mutant SF3B1-promoted isoform), with per-event, per-cohort range normalization. TCGA, The Cancer Genome Atlas. ( b ) Genes for which mutant SF3B1 promotes an NMD isoform (a3ss and se events only) in one or more cohorts. ( c ) CRISPR/Cas9-based positive selection screen targeting genes for which mutant SF3B1 promotes an NMD isoform. ( d ) Per-gene scatter plot comparing CRISPR screen enrichment (y axis) to differential splicing in TCGA UVM cohort (x axis). Pten , positive control. n=6 biologically independent experiments. Per-gene significance computed with two-sided CAMERA test. FDR computed with Benjamini-Hochberg method. ( e ) BRD9 RNA-seq read coverage in patient samples. N, number of patients. PE, BRD9 poison exon; 14 and 15, flanking constitutive exons. Repetitive elements from RepeatMasker . ( f ) Western blot for N-terminal HA-tagged endogenous BRD9 in MEL270 cells transduced with empty vector (EV) or doxycycline-inducible FLAG-SF3B1-WT/K700E. Representative images from n=3 biologically independent experiments.

Article Snippet: For western blotting, the following antibodies to the following proteins were used: BRD9 (Bethyl Laboratories; A303-781A and Active Motif; 61538), SF3B1/Sap-155 (MBL; D221-3), Flag-M2 (Sigma-Aldrich; F-1084), β-actin (Sigma-Aldrich; A-5441), GLTSCR1 (Santa Cruz Biotechnology; sc-515086), GLTSCR1L (Thermo Fisher Scientific; PA5-56126), BRM (Bethyl Laboratories; A303-015A), BRG1 (Santa Cruz Biotechnology; sc-17796), BAF155 (Santa Cruz Biotechnology; sc-48350), BAF60A (Santa Cruz Biotechnology; sc-135843), BAF47 (Santa Cruz Biotechnology; sc-166165), ARID1A (Santa Cruz Biotechnology; sc-373784), ARID2 (Santa Cruz Biotechnology; sc-166117), BRD7 (Thermo Fisher Scientific; PA5-49379), U2AF2 (Bethyl Laboratories; A303-665A), U2AF1 (Bethyl Laboratories; A302-080A), Histone H3 (Abcam; ab1791), HTRA1 (R&D systems; MAB2916-SP).

Techniques: Expressing, Mutagenesis, CRISPR, Selection, Positive Control, RNA Sequencing, Western Blot, Transduction, Plasmid Preparation

Journal: Nature

Article Title: Spliceosomal disruption of the non-canonical BAF complex in cancer

doi: 10.1038/s41586-019-1646-9

Figure Lengend Snippet:

Article Snippet: For western blotting, the following antibodies to the following proteins were used: BRD9 (Bethyl Laboratories; A303-781A and Active Motif; 61538), SF3B1/Sap-155 (MBL; D221-3), Flag-M2 (Sigma-Aldrich; F-1084), β-actin (Sigma-Aldrich; A-5441), GLTSCR1 (Santa Cruz Biotechnology; sc-515086), GLTSCR1L (Thermo Fisher Scientific; PA5-56126), BRM (Bethyl Laboratories; A303-015A), BRG1 (Santa Cruz Biotechnology; sc-17796), BAF155 (Santa Cruz Biotechnology; sc-48350), BAF60A (Santa Cruz Biotechnology; sc-135843), BAF47 (Santa Cruz Biotechnology; sc-166165), ARID1A (Santa Cruz Biotechnology; sc-373784), ARID2 (Santa Cruz Biotechnology; sc-166117), BRD7 (Thermo Fisher Scientific; PA5-49379), U2AF2 (Bethyl Laboratories; A303-665A), U2AF1 (Bethyl Laboratories; A302-080A), Histone H3 (Abcam; ab1791), HTRA1 (R&D systems; MAB2916-SP).

Techniques: